Novel inhibitors of cell adhesion molecule expression

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 22, 1996, Pages 2693-2698

  Dodd, Dharmpal S ^a   Shen, Zhongqi ^a   Nishi, Takao ^a,b   Graber, Norma ^a   Bealls, Dawson ^a   Fong, Miranda ^a   Ebert, Tracy ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DERMATITIS; DRUG STABILITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNE RESPONSE; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; LIVER; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0030593864     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00504-5     Document Type: Article

References (22)

1. 1. (a) Springer, T. A. Nature (London) 1990, 246, 425.
2. (b) Cronstein, B. N.; Weissmann, G. Arthritis Rheum. 1993, 36, 147.
3. (c) Cybulsky, M. I.; Gimbrone, M. A., Jr. Science 1991, 251, 788.
4. (d) Butcher, E. C. Cell 1991, 67, 1033.
5. 2. (a) Kavanaugh, A. F.; Davis, L. S.; Nichols, L. A.; Norris, S. H.; Rothlein, R.; Scharschmidt, L. A. Lipsky, P. E. Arthritis Rheum. 1994, 37, 992.
6. (b) Haug, C. E.; Colvin, R. B.; Delmonico, F. L.; Auchincloss, H.; Tolkoff-Rubin, N.; Preffer, F. I.; Rothlein, R.; Norris, S.; Scharschimdt, L.; Cosimi, A. B. A. Transplantation 1993, 55, 766.
7. 3. (a) Boschelli, D. H.; Kramer, J. B.; Connor, D. T.; Lesch, M. E.; Schrier, D. J.; Ferin, M. A.; Wright, C. D. J. Med. Chem. 1994, 37, 717.
8. (b) Sanfilippo, P. J.; Jetter, M. C.; Cordova, R.; Noe, R. A.; Chourmouzis, E.; Lau, C.; Wang, E. J. Med. Chem. 1995, 38, 1057.
9. (c) Burch, R. M.; Weitzberg, M.; Noronha-Blob, L.; Lowe, V. C.; Bator, J. M.; Permuttam, J.; Sullivan, J. P. Drug News Perspect. 1992, 5, 331.
10. (d) For an excellent review of agents that inhibit the leukocyte-endothelial cell binding, see: Boschelli, D. H.; Wright, C. D. Curr. Opin. Invest. Drugs 1993, 2, 723.
11. 4. (a) Chang, Y.-H.; Otterness, I. G. Eur. J. Pharm. 1981, 69, 155.
12. (b) Burch, R. M.; Connor, J. R.; Bator, J. M.; Weitzberg, M.; Laemont, K.; Noronha-Blob, L.; Sullivan, J. P.; Steranka, I. R. J. Pharmacol. Exp. Ther. 1992, 265, 933.
13. + ATPase inhibitor. For this case the attack of glutathione takes place at the C-2 of the benzimidazole. For a possible mechanism see Weidolf, L.; Karlsson, K.-E.; Nilsson, I. Drug Metab. Dispos. 1992, 20, 262.
14. 6. Replacement of the 1,3,4-oxadiazole with other heterocycles or replacement of the sulfoxide group of 1,3,4-oxadiazole with a carbonyl or a sulfone resulted in compounds that were inactive in the HUVEC assay. 7. For 2-mercapto-1,3,4-oxadiazole synthesis see: (a) Hoggarth, E. J. Chem. Soc. 1952, 4811.
15. (b) Lacasse, G.; Muchowski, J. M. Can. J. Chem. 1972, 50, 3082.
16. 8. (a) The ELISA for the determination of presence's of ELAM-1 and VCAM-1 is as follows: 96-well plates were coated with 2% gelatin (1 h). The excess gelatin was aspirated from the wells. HUVE cells were seeded at 20,000 cells/well in a 200 μL volume. The test compounds were dissolved in DMSO at a stock concentration of 50 mM. When the monolayer reached confluence (24-28h after seeding), the test compounds were added to the wells at a final concentrations of 30 μM, 10 μM, 3 μM, and 1 μM. Each compound was added in duplicate. The plates were incubated for 4 h at 37 °C. Then, IL-1 β was added at a final concentration of 2 ng/mL and the plates were incubated for 4 h at 37 °C. The supernatant was removed from the plates by decanting and the wells were washed 3X with 1% BSA-Dulbecco's PBS. Primary antibody [7A9 for ELAM-1 (Otsuka Pharm.) and 2G7 for VCAM-1 (Otsuka Pharm.)] at a concentration of 2.5 μg/mL in a 50 μL volume was added to each well. The plates were incubated at 4 °C for 45 min to 1 h. The wells were washed 3X with 1% BSA Dulbecco's PBS. Secondary antibody (F (Ab')2 fragment biotinylated goat antimouse IgG-IgM (Jackson ImmunoResearch) at 50 μL/well at a final dilution of 1:1,000 was added and incubated for 45 min to 1 h at 4 °C. The wells were washed 3X with 1% BSA-Dulbecco's PBS. Streptavidin-peroxidase (Sigma) at 50 μL/well with a final dilution of 1:30,000 was added to each well and the plates were incubated at 4°C for 30 min. Substrate solution (OPD tablets, citric acid buffer and hydrogen peroxide solution) was added at a concentration of 100 μL/well. The plates were incubated for 15 min at room temperature on plate shaker and the reaction was stopped with 12.5% sulfuric acid. Plates were read for absorbance at 492 nm and the reading for the duplicate averaged.
17. 9. (a) Morphological changes to the monolayer was determined by light microscopy. Toxicity was determined by crystal violet and MTT staining assays in the presence of the compounds at a 30 μM dose.
18. 10. (a) The 2-chloromethyl-3,5-dimethyl-4-methoxypyridine starting material can be prepared according to the procedure outlined in GB patent 2134523 and references ourtlined in Brändström, A.; Lindberg, P.; Bergman, N.; Alminger, T.; Ankner, K.; Junggren, U.; Lamm, B.; Nordberg, P.; Erickson, M.; Grundevik, I.; Hagin, I.; Hoffmann, K.; Johansson, S.; Larssom, S.; Lofberg, I.; Ohlson, K.; Björn, P.; Skånberg, I.; Tekenbergs-Hjelte, L. Acta Chem. Scand. 1989, 43, 536.
19. (b) 9-chloro-4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine precursor was prepared according to the procedure of Yamada, S.-I.; Goto, T.; Narita, S.-I. Chem. Pharm. Bull. 1994, 42, 718.
20. 11. A selective alkylation (nucleophilic attack on the C-2 of the 1,3,4-oxadiazole) of a receptor or an enzyme in the signal transduction pathway is suspected. This may explain the decrease in activity for those compounds that appear to be more stable to attack at C-2 of the oxadiazole.
21. 12. Mazel, P. In Fundamentals of Drug metabolism and Drug Disposition; La du, B. W., Mandel, H. G., Way, E. L., Eds.; Robert E. Krieger: Florida, 1971; pp 527-545.
22. 13. Procedure conditions: C57BL/6 mice were shaven and an IV solution injection of 100 μL of BSA at 10 mg/mL in saline was administered. This was followed immediately by an ID 25 μL injection of anti-BSA (0.5 mg/mL solution) along with the test compound or vehicle on a predetermined site on the backside of the mice. Four hours post injection, the animals were sacrificed and the skins removed and assayed for myeloperoxidase (MPO) activity as a measure of neutrophils, according to the procedure of Mulligan, M. S.; Ward, P. A. J. Imm. 1992, 149, 331. Each compound was tested on a group of seven mice.